Rigel Pharmaceuticals has recently started pre-clinical and clinical studies of IRAK1/4 inhibitor R835, demonstrating potential in murine models for multiple inflammatory diseases, including arthritis and lupus. The gene discussed is IRAK1; the disease is Arthritis.